Structural biology opens new perspectives for treating psychiatric disorders
Scientists have determined the structure of Glycine Transporter 1; the finding could open new avenues for developing therapeutics for psychiatric disorders
Glycine regulates neuronal activity in the brain
Glycine is the smallest amino acid - one of the building blocks of proteins. It acts also as a neurotransmitter in the brain, enabling neurons to communicate with each other and modulating neuronal activity. Many researchers have focused on increasing glycine levels in synapses to find an effective treatment for schizophrenia. This could be done using inhibitors targeting Glycine Transporter 1 (GlyT1), a protein that sits in neuronal cell membranes and is responsible for the uptake of glycine into neurons. However, the development of such drugs has been hampered because the 3D structure of GlyT1 was not known.
To determine the structure of GlyT1, researchers at the Danish Research Institute of Translational Neuroscience (DANDRITE), which is part of the Nordic EMBL Partnership for Molecular Medicine, F. Hoffmann-La END
Glycine is the smallest amino acid - one of the building blocks of proteins. It acts also as a neurotransmitter in the brain, enabling neurons to communicate with each other and modulating neuronal activity. Many researchers have focused on increasing glycine levels in synapses to find an effective treatment for schizophrenia. This could be done using inhibitors targeting Glycine Transporter 1 (GlyT1), a protein that sits in neuronal cell membranes and is responsible for the uptake of glycine into neurons. However, the development of such drugs has been hampered because the 3D structure of GlyT1 was not known.
To determine the structure of GlyT1, researchers at the Danish Research Institute of Translational Neuroscience (DANDRITE), which is part of the Nordic EMBL Partnership for Molecular Medicine, F. Hoffmann-La END